Annexon Q1 net loss $54.4M; cash $263.7M; GBS, GA programs advancing

Annexon, Inc.

2025-Q1 EPS reported -$0.37

Net loss $54.4M ($0.37/share) vs $25.2M ($0.21/share) in Q1 2024; R&D expense $48.2M, up from $21.0M.
Cash and short-term investments $263.7M; runway into H2 2026.
FDA meeting for tanruprubart (ANX005) in GBS scheduled Q2 2025; open-label FORWARD study starting Q2 2025; BLA submission planned.
Phase 3 ARCHER II for ANX007 in dry AMD with GA enrollment completion expected Q3 2025; top line data H2 2026.
Proof-of-concept trial for oral C1s inhibitor ANX1502 in cold agglutinin disease anticipated completion mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.